Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations

Amanda McCleery; Keith H Nuechterlein

doi:10.31887/DCNS.2019.21.3/amccleery

Back

Journal article

Open access

Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations

Amanda McCleery and Keith H Nuechterlein

Dialogues in clinical neuroscience, Vol.21(3), pp.239-248

09/2019

DOI: 10.31887/DCNS.2019.21.3/amccleery

PMCID: PMC6829172

PMID: 31749648

Files and links (1)

url

https://doi.org/10.31887/DCNS.2019.21.3/amccleeryView

Published (Version of record) Open Access

Abstract

Despite effective pharmacological treatments for psychotic symptoms (eg, hallucinations, delusions), functional outcomes for people with psychotic disorders are often disappointing. Although it is not included in the diagnostic criteria for psychotic disorders, cognitive impairment is one of the strongest determinants of community functioning in this clinical population, and thus it is an important target for intervention. In this review, we discuss the major areas of research regarding impaired cognition in psychotic illness. The specific topics covered include: (i) the prevalence of cognitive impairment in psychotic disorders; (ii) the profile and magnitude of cognitive impairment in psychotic disorders; (iii) the developmental course of cognitive impairment; (iv) the longitudinal stability of cognitive impairment; and (v) treatment approaches to improve cognitive performance in people with psychotic disorders. .

Cognitive Behavioral Therapy - methods

Prevalence

Antipsychotic Agents - therapeutic use

Cognitive Dysfunction - epidemiology

Humans

Psychotic Disorders - psychology

Cognitive Dysfunction - therapy

Cognitive Dysfunction - psychology

Nootropic Agents - therapeutic use

Treatment Outcome

Psychotic Disorders - epidemiology

Psychotic Disorders - therapy

Details

Title: Subtitle: Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations
Creators: Amanda McCleery - UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, US; VA Greater Los Angeles, VISN 22 MIRECC, Los Angeles, California, US
Keith H Nuechterlein - UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, US; UCLA Department of Psychology, Los Angeles, California, US
Resource Type: Journal article
Publication Details: Dialogues in clinical neuroscience, Vol.21(3), pp.239-248
DOI: 10.31887/DCNS.2019.21.3/amccleery
PMID: 31749648
PMCID: PMC6829172
NLM abbreviation: Dialogues Clin Neurosci
ISSN: 1294-8322
eISSN: 1958-5969
Publisher: France
Grant note: K23 MH108829 / NIMH NIH HHS R01 MH110544 / NIMH NIH HHS
Language: English
Date published: 09/2019
Academic Unit: Psychiatry; Psychological and Brain Sciences; Iowa Neuroscience Institute
Record Identifier: 9984065372202771

Metrics

22 Record Views

182 Times Cited - Web of Science

See more details